Ian Mortimer
Ian Mortimer is the CEO of Xenon Pharmaceuticals, a biotech firm focused on developing innovative therapies for neurological conditions. Under his leadership, Xenon has made significant strides in epilepsy drug development, particularly with the drug azetukalner, which is on the verge of potential FDA approval.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 7.00 | 0.16% | +0% | 38,005,238 | 62,406 | $1,700,000 | 2,791$ |
| Totals | 1 | 38,005,238 | 62,406 | $1,700,000 | 2,791$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Xenon CEO Ian Mortimer says the company has raised US$1.4-billion but would need more to take azetukalner to market.
7